Biocomposites Invests in Renovos Biologics

Biocomposites has taken a minority-share interest in Renovos Biologics. This investment allows Renovos access to Biocomposites’ expertise in the development to drug carriers for the continued development of RENOVITE for pre-market approval as a carrier for use in spine, trauma, and orthopedics. 
 
With this investment Renovos will also gain access to Biocomposites’ global distribution network. Biocomposties’ CEO Michael Harris will be joining Renovos’ board of directors. 
 
RENOVITE is a synthetic, biodegradable nanoclay carrier that can be used at the site of treatment to place pharmaceutical drugs and biologics. It can be injected through a 23-gauge cannula and supports minimally invasive procedures. Upon contact with physiological fluids, such as blood serum it turns into a stiff gel. RENOVITE requires a low dose of therapeutic drug to accelerate healing as a cell responsive carrier. 
 
Michael Harris commented, “the potential for RENOVITE as a next generation drug carrier that can enhance the activity of therapeutic drugs at lower does, whilst giving the surgeon much greater freedom to use in minimally invasive procedures, is very exciting. Following on for our recent acquisition of Atross in June this year, and Subiton and Synimed last year, Biocomposites has established itself as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.”
 
Renovos Biologics CEO Agnieszka Janeczek said, “we have long believed in the potential of RENOVITE to overcome the challenged in tissue regeneration by providing unprecedented retention of therapeutics at the site of repair. With the opportunity to partner with Biocomposites, Renovos now has access to their deep knowledge and expertise in drug developments, as well as their global distribution network as products come to market.”
 
Based in Keele, UK, Biocomposites is an international medical device company that engineers, manufactures, and markets products for use in infection management in bone and soft tissue. They develop calcium compounds and polymers for surgical use, their products regenerate bone and target infection, orthopedics, trauma, spine, foot, ankle, podiatry, and sports injuries. 
 
Renovos is a regenerative medicine company and developer of RENOVITE synthetic nanoclay for medical use. RENOVITE technology stems from research at the University of Southampton, UK and greatly improves the performance of a variety of regenerative products. RENOVITE offers an unprecedented retention of therapeutic agents at the target site of repair, mitigating the effects to a precisely controlled area, which creates a step-changing improvement in their efficacy, safety, and ease of use in biodegradable and injectable formulations.